Prospective multicenter validation of the independent prognostic value of the mitotic activity index in lymph node-negative breast cancer patients younger than 55 years

被引:92
作者
Baak, JPA
van Diest, PJ
Voorhorst, FJ
van der Wall, E
Beex, LVM
Vermorken, JB
Janssen, EAM
机构
[1] Stavanger Univ Hosp, Dept Pathol, N-4068 Stavanger, Norway
[2] Vrije Univ Amsterdam, Med Ctr, Dept Pathol, NL-1081 HV Amsterdam, Netherlands
[3] Vrije Univ Amsterdam, Med Ctr, Dept Epidemiol & Biostat, NL-1081 HV Amsterdam, Netherlands
[4] Vrije Univ Amsterdam, Med Ctr, Dept Med Oncol, NL-1081 HV Amsterdam, Netherlands
[5] Univ Bergen, Gade Inst, Bergen, Norway
[6] Univ Antwerp Hosp, Antwerp, Belgium
关键词
D O I
10.1200/JCO.2005.05.511
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose To validate the independent strong prognostic value of mitotic activity index (MAI) in lymph node (LN)-negative invasive breast cancer patients younger than 55 years in a nationwide multicenter prospective study. Patients and Methods Analysis of routinely assessed MAI and other prognosticators in 516 patients (median 118 months; range, 8 to 185 months), without systemic adjuvant therapy or follow-up previous malignancies. Results Distant metastases occurred in 127 patients (24.6%); 90 (17.4%) died as a result of metastases. MAI (< 10, >= 10) showed strong association with recurrence (hazard ratio [HR], 3.12; 95% CI, 2.17 to 4.50; P <=.0001) and mortality (HR, 4.42; 95% CI, 2.79 to 7.01; P </0001).The absolute difference in 10-year Kaplan-Meter estimates of time to distant recurrence as well as survival was 22% between MAI less than 10 versus >= 10. This effect was independent of age, estrogen receptor (ER) status, and tumor diameter (which were significant prognosticators). In multivariate analysis with regard to patient age, tumor diameter, grade, ER status, and the St Gallen criterion, MAI proved to be an independent and the strongest prognosticator. Tubular formation (TF) and nuclear atypia (NA), as constituents of (expert revised) grade, had no (for TF) or limited (for NA, P =.048) additional prognostic value to the MAI. In the group with MAI less than 10, MAI less than 3 versus more than 3 had additional value but the classical threshold of 0 to 5 v 6 to 10 did not. With this additional subdivision of MAI as less than 3, 3 to 9, and more than 9, NA lost its additive prognostic value. Conclusion The MAI is the strongest, most widely available, easily assessable, inexpensive, well-reproducible prognosticator and is well suited to routinely differentiate between high- and low-risk LN-negative breast cancer patients younger than 55 years.
引用
收藏
页码:5993 / 6001
页数:9
相关论文
共 46 条
[1]  
Abe O, 1998, LANCET, V352, P930
[2]   Disease-free survival advantage of adjuvant cyclophosphamide, methotrexate, and fluorouracil in patients with node-negative, rapidly proliferating breast cancer: A randomized multicenter study [J].
Amadori, D ;
Nanni, O ;
Marangolo, M ;
Pacini, P ;
Ravaioli, A ;
Rossi, A ;
Gambi, A ;
Catalano, G ;
Perroni, D ;
Scarpi, E ;
Giunchi, DC ;
Tienghi, A ;
Becciolini, A ;
Volpi, A .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (17) :3125-3134
[3]  
[Anonymous], 1981, HIST TYP BREAST TUM
[4]  
BAAK JPA, 1985, CANCER, V56, P374, DOI 10.1002/1097-0142(19850715)56:2<374::AID-CNCR2820560229>3.0.CO
[5]  
2-9
[6]   The framework of pathology: Good Laboratory Practice by quantitative and molecular methods [J].
Baak, JPA .
JOURNAL OF PATHOLOGY, 2002, 198 (03) :277-283
[7]   THE MULTICENTER MORPHOMETRIC MAMMARY-CARCINOMA PROJECT (MMMCP) - A NATIONWIDE PROSPECTIVE-STUDY ON REPRODUCIBILITY AND PROGNOSTIC POWER OF ROUTINE QUANTITATIVE ASSESSMENTS IN THE NETHERLANDS [J].
BAAK, JPA ;
VANDIEST, PJ ;
ARIENS, AT ;
VANBEEK, MWPM ;
BELLOT, SM ;
FIJNHEER, J ;
VANGORP, LHM ;
KWEE, WS ;
LOS, J ;
PETERSE, HC ;
RUITENBERG, HM ;
SCHAPERS, RFM ;
SCHIPPER, MEI ;
SOMSEN, JG .
PATHOLOGY RESEARCH AND PRACTICE, 1989, 185 (05) :664-670
[8]   The influence of fixation delay on mitotic activity and flow cytometric cell cycle variables [J].
Bergers, E ;
Jannink, I ;
vanDiest, PI ;
Cuesta, MA ;
Meyer, S ;
vanMourik, JC ;
Baak, JPA .
HUMAN PATHOLOGY, 1997, 28 (01) :95-100
[9]  
Bergers E, 1997, INT J CANCER, V74, P260, DOI 10.1002/(SICI)1097-0215(19970620)74:3<260::AID-IJC5>3.0.CO
[10]  
2-X